Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 24.79M P/E - EPS this Y - Ern Qtrly Grth -
Income -20.06M Forward P/E -1.42 EPS next Y - 50D Avg Chg -7.00%
Sales 1.08M PEG - EPS past 5Y - 200D Avg Chg 4.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -46.00%
Recommedations 2.00 Quick Ratio 1.11 Shares Outstanding 28.72M 52W Low Chg 122.00%
Insider Own 39.48% ROA -143.52% Shares Float 15.87M Beta -0.15
Inst Own 9.76% ROE -730.48% Shares Shorted/Prior 45.61K/63.34K Price 1.49
Gross Margin 90.85% Profit Margin - Avg. Volume 91,743 Target Price 4.00
Oper. Margin -1,811.99% Earnings Date May 13 Volume 45,296 Change 2.76%
About Cyclo Therapeutics, Inc.

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

Cyclo Therapeutics, Inc. News
04/10/24 Pleasing Signs As A Number Of Insiders Buy Cyclo Therapeutics Stock
03/18/24 Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
03/14/24 Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
03/13/24 Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
01/29/24 Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office
12/27/23 Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
12/18/23 Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1
12/14/23 Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results
11/21/23 Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024
11/15/23 Cyclo Therapeutics Reports Third Quarter 2023 Financial Results
11/02/23 Several Insiders Invested In Cyclo Therapeutics Flagging Positive News
10/30/23 Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results
07:05 AM Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million
10/05/23 Cyclo Therapeutics to Present at 8th Annual Dawson James Conference
09/21/23 Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
09/21/23 Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement
08/15/23 Cyclo Therapeutics Reports Second Quarter 2023 Financial Results
08/02/23 Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.
06/29/23 Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1
06/13/23 Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update
CYTH Chatroom

User Image TouchMikeStock Posted - 16 minutes ago

$CYTH https://ascendiant.com/ascendiant-initiates-equity-research-coverage-on-cyclo-therapeutics-inc-nasdaq-cyth/ Link to their write up. Seems like they will be investing.

User Image TheRipple Posted - 9 hours ago

$CYTH Haven’t forgotten you but in due time. Still believe you’re in transition.

User Image ButterCall Posted - 15 hours ago

$CYTH I expect this rally, which began today, to take us 100% higher from here and exceed the 52 week highs set last June. Lines up nicely with Ascendiant's just released PT of $2.60. See you folks over $2 late May/early June

User Image BelgianStokker Posted - 16 hours ago

$CYTH go go go

User Image Sashko2018 Posted - 17 hours ago

$CYTH drop the news already sent it

User Image Sashko2018 Posted - 17 hours ago

$CYTH let’s go

User Image OGLUCIDBULL Posted - 21 hours ago

$CYTH finally in at 1.2…5000 delta

User Image ButterCall Posted - 22 hours ago

$CYTH Sneaky nice start to the week, aggressive bid raising happening in the first 30 mins of trade. Love to see us reclaim the $1.3s today

User Image ButterCall Posted - 22 hours ago

$CYTH How does Ascendiant know my cost basis? LFGGGGGGGGGG

User Image DonCorleone77 Posted - 1 day ago

$CYTH Cyclo Therapeutics initiated with a Buy at Ascendiant Ascendiant initiated coverage of Cyclo Therapeutics with a Buy rating and $2.60 price target. Cyclo is a drug company specializing in cyclodextrin-based therapies for neuro-degenerative diseases, including Niemann-pick type C and Alzheimer's disease, the analyst tells investors in a research note. The firm says the patient cultivation of the company's cyclodextrin platform brings it close to breakthrough therapies.

User Image erevnon Posted - 1 day ago

Ascendiant Capital initiates coverage on Cyclo Therapeutics $CYTH at Buy and a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

User Image CYTHboundtoblow Posted - 2 days ago

$CYTH

User Image sg44 Posted - 2 days ago

$RFL $CYTH interesting analysis from Barbara Ryan RFL advisor https://www.pharmexec.com/view/the-biotech-rally-has-legs-but-rising-tide-isn-t-lifting-all-boats

User Image VGtrader Posted - 3 days ago

$CYTH interesting junction we are in, watching if the ascending triangle formation holds within the next days. Ascending triangles are a generally a neutral pattern that can go either ways. Now, I am optimistic about the market for the 2nd half of the year, as I mentioned before. Israel is not going to be allowed to escalate with Iran, -US got their reins, as we all know- and tensions in the middle East should slowly ease. While rate cuts may be pushed towards the last quarter, I feel we will see a push in the markets after this last drawback clears. CYTH should see an easy rebound to 1.90, but still strong resistance there and at 2.50. If tensions escalate, it wouldn't be a surprise for the SP to come down to 0.94 levels, turning the triangle into a regular sideway channel, which would be another excellent loading area for longs. All DD the same than before. Have a fantastic Friday, you all.

User Image TouchMikeStock Posted - 3 days ago

$CYTH volume will blow you away today.

User Image marinax Posted - 4 days ago

$CYTH once a shit always shit . but i am holding my shares from last 3 years . everybody sell company sell but i am not selling my shares .

User Image Moksi Posted - 4 days ago

$CYTH super excited

User Image brallt Posted - 5 days ago

$CYTH Buy when others are fearful. The fear seems to be strong. I may have to start a small position. Just like a chat can be too bullish. so can it be too bearish. It looks like sell pressure has lessened and they are trying to convince themselves that it's not finding support.

User Image BidnessMindUrOwn Posted - 5 days ago

$CYTH Dumped this POS 12/14 at $1.21 after holding this turd for years. Never was worth a chit. Still isn't .. I think it might be a scam.

User Image Roadtofruition Posted - 6 days ago

@Miko_Vakilla oh...When a dozen accounts that Cyclo does not operate all released a patent allowance for $Cyth in one of the worst disease in the world with no known cure. Yeah pretty amazing Scott was able to pump it up , even though he has no access to the followers of all those accounts or Patent office.

User Image GansoManso Posted - 6 days ago

$CYTH This is a struggling cyclodextrin company claiming to be running studies on a drug, which by the way has been tried before and failed, in order to justify the Fine family dilution scam. There are much better investments out there. Any serious investor would never consider buying shares in this company. This will meet the same fate as SEEL, another MWT pick, lol.

User Image sg44 Posted - 6 days ago

$CYTH bought the dip

User Image Curate Posted - 6 days ago

@Rat_Bastard2 @ButterCall meh. Everything is down today. People are finally realizing it’ll take awhile for the FED to cut rates. I really don’t feel like this drop relates to anything specific about $CYTH itself, other than it being a risky investment which ultimately benefits from low-interest rate environments.

User Image Rat_Bastard2 Posted - 6 days ago

$CYTH @ButterCall said it would be like this. I’m unshaken.

User Image DottoreMK Posted - 6 days ago

$CYTH Even Jaggy runnin🤷🏻‍♂️🤷🏻‍♂️POS!

User Image GansoManso Posted - 6 days ago

@ButterCall Channeling the late MWT... It will happen on Friday the 13th of September. Mark it and share widely!

User Image Miko_Vakilla Posted - 1 week ago

$CYTH I know right? Looks like Remi and the FBI man are going to jail for the fraud that the shorts say they are. Remi should have kept pumping like Scott & Family. /s Why would SAVA stop the dilution when they need cash? Maybe a partnership is coming with a CVR. I doubt RFL is the partner.

User Image ButterCall Posted - 1 week ago

@GansoManso Say it!

User Image ButterCall Posted - 1 week ago

$CYTH Appears we still have at least a little bit of work to do on the downside around $1.15. Would love to see it wick off that trendline and return to the MA collection area betw. $1.45-1.60. The long term MA to beat has come down considerably from my last post; currently sitting @ $2.43. Sideways consolidation is not our enemy as we work off a 5-year long -99% decline in price. News soon? If not, insider buys soon? Scott? FPO? Anybody? Lol.......

User Image Pizzino Posted - 1 week ago

$CYTH shares available on iborrow have jump to 400k

Analyst Ratings
Ascendiant Capital Buy Apr 22, 24
Maxim Group Buy Sep 27, 23
Maxim Group Hold Mar 21, 23
Maxim Group Buy Dec 17, 20
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
TATE JEFFREY Chief Operating Offi.. Chief Operating Officer Apr 20 Buy 0.71 29,941 21,258 62,101 04/24/23
FINE N SCOTT Chief Executive Offi.. Chief Executive Officer Apr 20 Buy 0.71 299,402 212,575 444,402 04/24/23
Sieger Markus Director Director Apr 20 Buy 0.71 59,881 42,516 161,051 04/24/23
Ostronic Francis Patrick Director Director Apr 20 Buy 0.71 59,881 42,516 222,371 04/24/23
Ostronic Francis Patrick Director Director Sep 21 Buy 1.76 5,000 8,800 150,687 09/22/22
Ostronic Francis Patrick Director Director May 20 Buy 2.02 5,000 10,100 138,525 05/23/22
TATE JEFFREY Chief Operating Offi.. Chief Operating Officer May 16 Buy 2.118 3,000 6,354 32,160 05/16/22
TATE JEFFREY Chief Operating Offi.. Chief Operating Officer Apr 28 Buy 2.64 2,000 5,280 29,160 04/29/22
Sieger Markus Director Director Mar 29 Buy 2.73 10,000 27,300 81,689 03/30/22
Ostronic Francis Patrick Director Director Jan 24 Buy 3.75 2,000 7,500 113,211 01/24/22
FINE N SCOTT Chief Executive Offi.. Chief Executive Officer Jan 19 Buy 3.89 5,000 19,450 134,666 01/19/22
Ostronic Francis Patrick Director Director Jan 19 Buy 4 1,132 4,528 111,211 01/19/22
Ostronic Francis Patrick Director Director Jan 14 Buy 4 1,731 6,924 110,079 01/18/22